Meeting
2022 ASCO Annual Meeting
Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51.
Authors
Brian Ball
City of Hope, Duarte, CA
Brian Ball , Gautam Borthakur , Anthony Selwyn Stein , Kyle Chan , Dung Luong Thai , Eytan Stein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04243785
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7030)
DOI
10.1200/JCO.2022.40.16_suppl.7030
Abstract #
7030
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2016 ASCO Annual Meeting
Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.
First Author: Catherine Choy Smith
Poster
2023 ASCO Annual Meeting
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.
First Author: Martin H. Dreyling
Poster
2023 ASCO Annual Meeting
Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).
First Author: Nicholas Stong